Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
NCT01908595 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480
Last updated 2015-09-02
Summary
This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.
Conditions
Interventions
- DRUG
-
M518101
Sponsors & Collaborators
-
Maruho North America Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
NCT02931838 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
NCT06077331 ·Status: RECRUITING ·Phase: PHASE2
-
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT01045577 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT05364554 ·Status: COMPLETED ·Phase: PHASE2
-
Immunologic Response to Secukinumab in Plaque Psoriasis
NCT02592018 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
NCT01510951 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
NCT01365455 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
NCT05531682 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
NCT03337022 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
NCT04316585 ·Status: COMPLETED ·Phase: PHASE1
-
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
NCT01519089 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
NCT06176508 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
NCT01154101 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
NCT00338143 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
NCT03535194 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects
NCT03018509 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
NCT06926582 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
NCT02618759 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03482011 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
NCT01617018 ·Status: COMPLETED
-
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
NCT02502188 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
NCT01670513 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2